Patient Reported Outcome Measures in a Large Cohort of Patients with Type 1 Gaucher Disease

Overview

Journal Orphanet J Rare Dis

Publisher Biomed Central

Specialty General Medicine

Date 2020 Oct 14

PMID 33050940

Citations 11

Authors

Tama Dinur

Majdolen Istaiti

Dafna Frydman

Michal Becker-Cohen

Jeff Szer

Ari Zimran

Shoshana Revel-Vilk

Affiliations

Soon will be listed here.

Abstract

Background: It is now acknowledged that the input of patients in health outcome assessment is vital to understanding the impact of diseases and interventions for those diseases. This study is the first report of patient-reported outcome measures (PROM) in a large cohort of patients with type 1 Gaucher disease (GD1) enabling us to study predictors of the reported outcomes.

Method: The PROM was sent via a mobile phone survey to 405 adult patients with GD1. Demographics, clinical data, and treatment status were extracted from clinic charts. Age, sex, severity score index (SSI) at presentation and treatment status were used as variables to assess outcomes.

Results: A total of 192 patients with GD1 (111 females) responded (47.4% response rate), of whom 124 (64.5%) had received GD1-specific therapy. Around 40% of patients reported that GD had restricted their education/job and fun activities and were concerned about being emotional and financial burdens on others. Concerns regarding the risk of bone disease and Parkinson disease were also high (60%). The severity of GD1 (reflected by the need for GD1-specific therapy and a high SSI) was associated with GD1-related restrictions and concerns, fatigue, physical weakness, bone pain, and worry regarding the future.

Conclusions: The use of GD1 specific PROM highlights personal problems that are not captured by traditional outcome parameters and that need to be addressed to improve health-related quality of life. Validated PROM should be included among the outcome measures in clinical practice and future prospective studies for patients with chronic and rare diseases.

Citing Articles

The Unmet Needs of Lysosomal Storage Disorders from Early Diagnosis to Caregiving Pathways: An Italian Perspective.

Castaman G, Linari S, Barbato A, Costantino N, Dionisi-Vici C, Menni F J Clin Med. 2024; 13(22).

PMID: 39598125 PMC: 11595360. DOI: 10.3390/jcm13226981.

Measuring health related quality of life (HRQoL) in Lysosomal Storage Disorders (LSDs): a rapid scoping review of available tools and domains.

McDool E, Powell P, Carlton J Orphanet J Rare Dis. 2024; 19(1):252.

PMID: 38965628 PMC: 11225496. DOI: 10.1186/s13023-024-03256-0.

Noninvasive DBS-Based Approaches to Assist Clinical Diagnosis and Treatment Monitoring of Gaucher Disease.

Rossi C, Ferrante R, Valentinuzzi S, Zucchelli M, Buccolini C, Di Rado S Biomedicines. 2023; 11(10).

PMID: 37893047 PMC: 10604114. DOI: 10.3390/biomedicines11102672.

The Complexities of Diagnosis with Co-Existing Gaucher Disease and Hemato-Oncology-A Case Report and Review of the Literature.

Sudul P, Piatkowska-Jakubas B, Pawlinski L, Galazka K, Sacha T, Kiec-Wilk B J Clin Med. 2023; 12(17).

PMID: 37685585 PMC: 10488105. DOI: 10.3390/jcm12175518.

Patient-reported outcomes in Gaucher's disease: a systematic review.

Feng J, Gao Z, Shi Z, Wang Y, Li S Orphanet J Rare Dis. 2023; 18(1):244.

PMID: 37626429 PMC: 10463869. DOI: 10.1186/s13023-023-02844-w.

References

Bae W, Kwon J, Lee H, Lee S, Song E, Shim H . Feasibility and accessibility of electronic patient-reported outcome measures using a smartphone during routine chemotherapy: a pilot study. Support Care Cancer. 2018; 26(11):3721-3728. DOI: 10.1007/s00520-018-4232-z. View

Wagner V, Northrup H, Hashmi S, Nguyen J, Koenig M, Davis J . Attitudes of Individuals with Gaucher Disease toward Substrate Reduction Therapies. J Genet Couns. 2017; 27(1):169-176. PMC: 5794801. DOI: 10.1007/s10897-017-0137-0. View

Ben Chetrit E, Alcalay R, Steiner-Birmanns B, Altarescu G, Phillips M, Elstein D . Phenotype in patients with Gaucher disease and Parkinson disease. Blood Cells Mol Dis. 2012; 50(3):218-21. DOI: 10.1016/j.bcmd.2012.11.011. View

Gary S, Ryan E, Steward A, Sidransky E . Recent advances in the diagnosis and management of Gaucher disease. Expert Rev Endocrinol Metab. 2018; 13(2):107-118. PMC: 6129380. DOI: 10.1080/17446651.2018.1445524. View

Black N . Patient reported outcome measures could help transform healthcare. BMJ. 2013; 346:f167. DOI: 10.1136/bmj.f167. View

Zion Y, Pappadopulos E, Wajnrajch M, Rosenbaum H . Rethinking fatigue in Gaucher disease. Orphanet J Rare Dis. 2016; 11(1):53. PMC: 4850725. DOI: 10.1186/s13023-016-0435-x. View

Jian J, Zhao S, Tian Q, Liu H, Zhao Y, Chen W . Association Between Progranulin and Gaucher Disease. EBioMedicine. 2016; 11:127-137. PMC: 5049935. DOI: 10.1016/j.ebiom.2016.08.004. View

Rosenbloom B, Weinreb N, Zimran A, Kacena K, Charrow J, Ward E . Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood. 2005; 105(12):4569-72. DOI: 10.1182/blood-2004-12-4672. View

Alcalay R, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C . Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol. 2014; 71(6):752-7. PMC: 4082726. DOI: 10.1001/jamaneurol.2014.313. View

10.

Babajani G, Tropak M, Mahuran D, Kermode A . Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant. Mol Genet Metab. 2012; 106(3):323-9. PMC: 3425598. DOI: 10.1016/j.ymgme.2012.04.018. View

11.

Aflaki E, Westbroek W, Sidransky E . The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease. Neuron. 2017; 93(4):737-746. PMC: 5327952. DOI: 10.1016/j.neuron.2017.01.018. View

12.

Beutler E . Economic malpractice in the treatment of Gaucher's disease. Am J Med. 1994; 97(1):1-2. DOI: 10.1016/0002-9343(94)90041-8. View

13.

Zimran A, Sorge J, Gross E, Kubitz M, West C, Beutler E . Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet. 1989; 2(8659):349-52. DOI: 10.1016/s0140-6736(89)90536-9. View

14.

Maor G, Rencus-Lazar S, Filocamo M, Steller H, Segal D, Horowitz M . Unfolded protein response in Gaucher disease: from human to Drosophila. Orphanet J Rare Dis. 2013; 8:140. PMC: 3819655. DOI: 10.1186/1750-1172-8-140. View

15.

Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Ferguson J . Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018; 13(1):61. PMC: 5914068. DOI: 10.1186/s13023-018-0810-x. View

16.

Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D . Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis. 2005; 34(3):197-200. DOI: 10.1016/j.bcmd.2005.03.004. View

17.

Biegstraaten M, Cox T, Belmatoug N, Berger M, Collin-Histed T, Vom Dahl S . Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. Blood Cells Mol Dis. 2017; 68:203-208. DOI: 10.1016/j.bcmd.2016.10.008. View

18.

Revel-Vilk S, Szer J, Mehta A, Zimran A . How we manage Gaucher Disease in the era of choices. Br J Haematol. 2018; 182(4):467-480. DOI: 10.1111/bjh.15402. View

19.

Zimran A, Belmatoug N, Bembi B, Deegan P, Elstein D, Fernandez-Sasso D . Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS). Am J Hematol. 2017; 93(2):205-212. PMC: 5814927. DOI: 10.1002/ajh.24957. View

20.

Weinreb N, Mistry P, Rosenbloom B, Dhodapkar M . MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association. Blood. 2018; 131(22):2500-2501. PMC: 5981170. DOI: 10.1182/blood-2018-02-834689. View